COURSE试验及未来展望：用生物制剂重新思考慢性阻塞性肺疾病急性加重的管理 - Suppr

Suppr

超能文献

The COURSE trial and beyond: rethinking chronic obstructive pulmonary disease exacerbation management with biologics.

作者信息

Kashizaki Fumihiro, Chen Hao

机构信息

Department of Respiratory Medicine, Yokohama Minami Kyosai Hospital, Kanagawa, Japan.

出版信息

J Thorac Dis. 2025 Aug 31;17(8):6356-6363. doi: 10.21037/jtd-2025-705. Epub 2025 Aug 27.

DOI:10.21037/jtd-2025-705

PMID:40950879

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12433091/

Abstract

摘要

相似文献

The COURSE trial and beyond: rethinking chronic obstructive pulmonary disease exacerbation management with biologics.COURSE试验及未来展望：用生物制剂重新思考慢性阻塞性肺疾病急性加重的管理

J Thorac Dis. 2025 Aug 31;17(8):6356-6363. doi: 10.21037/jtd-2025-705. Epub 2025 Aug 27.

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.特泽佩umab对比安慰剂治疗中重度至非常重度慢性阻塞性肺疾病成人患者的疗效和安全性（COURSE）：一项随机、安慰剂对照的2a期试验

Lancet Respir Med. 2025 Jan;13(1):47-58. doi: 10.1016/S2213-2600(24)00324-2. Epub 2024 Dec 6.

Multi-Criteria Decision Analysis of Biologics in Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病中生物制剂的多标准决策分析

Int J Chron Obstruct Pulmon Dis. 2025 Sep 10;20:3163-3173. doi: 10.2147/COPD.S550144. eCollection 2025.

Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT.用于指导慢性阻塞性肺疾病急性加重期抗生素自我治疗的痰液颜色图表：Colour-COPD随机对照试验

Health Technol Assess. 2025 May;29(28):1-42. doi: 10.3310/KPFD5558.

Real-world effectiveness study of guideline-directed COPD STANDARDized management in patients with chronic obstructive pulmonary disease: a cluster randomised trial design.慢性阻塞性肺疾病患者中指南指导的慢性阻塞性肺疾病标准化管理的真实世界有效性研究：一项整群随机试验设计

BMJ Open Respir Res. 2025 Jul 7;12(1):e002768. doi: 10.1136/bmjresp-2024-002768.

Exacerbation control in chronic obstructive pulmonary disease with tezepelumab: insights from the COURSE trial.使用tezepelumab控制慢性阻塞性肺疾病急性加重：来自COURSE试验的见解。

J Thorac Dis. 2025 Jul 31;17(7):4379-4382. doi: 10.21037/jtd-2025-769. Epub 2025 Jul 29.

Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study.tezepelumab在美国不同严重哮喘患者群体中的有效性和安全性：PASSAGE研究的初步结果

Adv Ther. 2025 Jul;42(7):3334-3353. doi: 10.1007/s12325-025-03231-6. Epub 2025 May 19.

Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.特泽布尔单抗与其他生物制剂治疗重度哮喘的比较：系统评价和间接治疗比较。

J Med Econ. 2022 Jan-Dec;25(1):679-690. doi: 10.1080/13696998.2022.2074195.

Drug evaluation: mepolizumab in chronic obstructive pulmonary disease.药物评估：美泊利单抗治疗慢性阻塞性肺疾病

Immunotherapy. 2025 Apr;17(6):399-408. doi: 10.1080/1750743X.2025.2504326. Epub 2025 May 14.

Risk of Severe Exacerbation Associated with Gabapentinoid Use in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.慢性阻塞性肺疾病患者使用加巴喷丁类药物相关的严重急性加重风险：一项基于人群的队列研究

COPD. 2025 Dec;22(1):2534002. doi: 10.1080/15412555.2025.2534002. Epub 2025 Jul 23.

本文引用的文献

Factors Influencing the Efficacy and Safety of Monoclonal Antibody Biologics in Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials.影响单克隆抗体生物制剂在慢性阻塞性肺疾病中疗效和安全性的因素：一项随机对照试验的荟萃分析

Lung. 2025 Mar 14;203(1):46. doi: 10.1007/s00408-025-00795-6.

Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype.美泊利单抗预防嗜酸性粒细胞型慢性阻塞性肺疾病的急性加重

N Engl J Med. 2025 May 1;392(17):1710-1720. doi: 10.1056/NEJMoa2413181.

A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.一项评估IL-33单克隆抗体托扎单抗治疗慢性阻塞性肺疾病患者的2a期试验：FRONTIER-4。

Eur Respir J. 2025 Jul 14;66(1). doi: 10.1183/13993003.02231-2024. Print 2025 Jul.

Biomarkers of inflammation associated with radon exposure in the School Inner-City Asthma Study (SICAS).学校内城哮喘研究（SICAS）中与氡暴露相关的炎症生物标志物。

J Allergy Clin Immunol. 2025 Jun;155(6):1866-1872. doi: 10.1016/j.jaci.2025.01.033. Epub 2025 Feb 7.

Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials.度普利尤单抗用于治疗伴有2型炎症的慢性阻塞性肺疾病：两项3期随机双盲安慰剂对照试验的汇总分析

Lancet Respir Med. 2025 Mar;13(3):234-243. doi: 10.1016/S2213-2600(24)00409-0. Epub 2025 Jan 31.

TSLP and TSLPr Expression and Localization in the Airways of COPD and Non-COPD Patients.TSLP和TSLPr在慢性阻塞性肺疾病（COPD）和非COPD患者气道中的表达及定位

Eur J Immunol. 2025 Jan;55(1):e202451480. doi: 10.1002/eji.202451480.

Lancet Respir Med. 2025 Jan;13(1):47-58. doi: 10.1016/S2213-2600(24)00324-2. Epub 2024 Dec 6.

Real-World and Patient-Reported Outcomes of Dupilumab and Other Biological Drugs for Chronic Obstructive Pulmonary Disease-A Systematic Review.度普利尤单抗及其他生物药物治疗慢性阻塞性肺疾病的真实世界和患者报告结局——一项系统评价

Diagnostics (Basel). 2024 Oct 26;14(21):2390. doi: 10.3390/diagnostics14212390.

Clinical effectiveness and safety of dupilumab in patients with chronic obstructive pulmonary disease: A 7-year population-based cohort study.度普利尤单抗治疗慢性阻塞性肺疾病患者的临床疗效和安全性：一项基于人群的7年队列研究。

J Allergy Clin Immunol. 2025 Jan;155(1):219-222.e1. doi: 10.1016/j.jaci.2024.09.019. Epub 2024 Oct 3.

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.针对伴有血液嗜酸性粒细胞证据的 2 型炎症 COPD 患者的度普利尤单抗。

N Engl J Med. 2024 Jun 27;390(24):2274-2283. doi: 10.1056/NEJMoa2401304. Epub 2024 May 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验